白细胞介素-2加强小鼠T淋巴细胞产生白细胞介素-3

本文报道了白细胞介素-2(IL-2)刺激ConA(5μg/ml)活化的小鼠T细胞产生的条件培养液(TCM)中含有CFU-GEMM诱导活性。这种CFU-GEMM诱导活性的生成在IL-2作用后48h达到高峰。特异性抗IL-3单克降抗体可以完全中和该条件培养液中的CFU-GEMM诱导活性。进一步证明,TCM可以刺激IL-3依赖细胞系FDC-P_1细胞的增殖;在IL-2作用于ConA活化的T细胞后可促进其细胞表达高水平的IL-3mRNA。这些结果表明IL-2可以加强小鼠T细胞产生IL-3。     

视网膜神经节细胞的纯化和体外存活

我们用特异性抗体Thy1.1结合尼龙筛方法分离和纯化新生大鼠视网膜神经节细胞,比较顶盖提取液对这些纯化细胞的作用。预先以快蓝(fast blue,FB)逆行标记的视网膜细胞悬液,接种在包被了Thy1.1抗体的培养皿上30分钟,冲洗未粘附的细胞,显微镜下计数粘附细胞中FB标记的视网膜神经节细胞纯度的百分比,最高为95%。用孔径15μm尼龙筛方法分离的纯度仅为60±5%。上述两种方法纯化的视网膜神经节细胞,仅在有顶盖提取液存在时,细胞存活并生长活跃,胞体大且有突起伸出。MTT微量比色法测定培养24小时纯化细胞存活的光密度(OD)值,显示以Thy1.1特异性抗体纯化的细胞,其OD值比值(+Te/-Te)是12.3(0.111/0.009);以尼龙筛纯化的OD值比值(+Te/-Te)是6.4(0.102/0.016);未经纯化的OD值比值(+Te/-Te)是3.8(0.095/0.025)。在上述三组中,加Te与无Te细胞生存的OD值比较,相差均非常显著(P<0.01)。结论:在纯化的视网膜神经节细胞的培养中,由于排除了其他细胞所引起的非特异性反应,神经节细胞能够更直接地反映顶盖提取液的生物效应;视网膜神经节细胞纯度越高,其作用越显著。     

猪白细胞介素2与融合白细胞介素4/6基因共表达的免疫效应研究

目的构建猪融合白细胞介素4/6与猪白细胞介素2基因的共表达载体,研究其共表达对小鼠免疫的协同效应。方法以2A自剪接技术首次构建猪融合白细胞介素4/6与白细胞介素2基因的共表达重组质粒,以壳聚糖纳米材料包裹制成纳米颗粒,进行体外转染HEK293细胞,提取总RNA进行RT-PCR分析,最后肌肉注射小鼠进行体内实验并分析。结果成功构建了重组共表达质粒VRIL4/6-2;壳聚糖包裹后转染HEK293细胞,48 h后收集细胞,RT-PCR检测显示目的基因能够在HEK293细胞中高效地转录与表达。小鼠接种实验结果表明,实验组血清中的IgG和IgG2a的含量比对照组显著增加,并且VRIL4/6-2-CS接种组的小鼠体液免疫水平明显增高(P0.05);VRIL4/6-2实验组的CD4+淋巴细胞显著多于其它实验组(P0.05);实验组IL-2、IL-4、IL-6、IL-23基因的表达水平明显高于对照组(P0.05),实验组小鼠外周血白细胞、血小板和血红蛋白的含量均显著高于对照组(P0.05)。结论 VRIL4/6-2共表达质粒能够更好的增强动物体液免疫和细胞免疫机能,可作为提高动物体液免疫和细胞免疫的经济高效安全新型免疫调节剂,具有潜在的重要应用前景。     

脂多糖通过诱导白细胞介素-1的生成引起迷走传入神经活动

为探讨脂多糖（liopoplysaccharide,LPS）引起迷走传入神经活动是否可能通过白细胞介素-1（interleukin-1,IL-1）的作用,将Wistar大鼠随机分为LPS实验组和生理盐水对照组,用免疫组织化学方法检测迷走神经结状神经节c-Fos及CD14的表达以及腹腔迷走神经周围Mac-1阳性巨噬细胞（macrophage,Mφ）。用L929细胞增殖法检测LPS刺激Mφ上清IL-1的生物活性。用原位杂交的方法检测迷走神经结状神经节I型白细胞介素-1受体（IL-1R I）mRNA的表达。结果显示,LPS组迷走神经结状神经节神经元c-Fos蛋白表达为阳性,而对照组迷走神经结状神经节神经元c-Fos蛋白表达为阴性。LPS注射后1h,见腹腔迷走神经周围Mφ数量明显增多。Mφ在LPS刺激后45min、1h和2h时,IL-1生成明显增高,LPS组迷走神经结状神经节IL-1R I mRNA表达为阳性。以上结果提示,LPS引起迷走传入神经活动可能通过IL-1的作用。     

白细胞介素-17受体C

白细胞介素-17受体C(interleukin-17 receptor C,IL-17RC)是新发现的IL-17家族受体,组织分布广泛,如分布于大多数血管、淋巴管的内皮细胞、鳞状上皮等。IL-17RC是IL-17F的受体,也可以与IL-17A以及IL-17A、IL-17F组成的复合物结合。此外,IL-17RC还可与IL-17RA组成受体复合物后再与相应的配体结合,从而激活细胞内的信号转导系统。     

猪白细胞介素-2和融合抗菌肽重组酵母菌构建及其对小鼠免疫和生长的协同效应

为了开发经济实用的新型免疫调节剂,以2A自剪切技术构建重组毕赤酵母Pichiapastoris共同表达猪白细胞介素-2(IL-2)和融合抗菌肽基因,然后以重组基因工程酵母菌饲喂ICR小鼠,以实时荧光定量PCR、ELISA和流式细胞计数评估其对小鼠免疫力和生长的影响。实验结果显示,处理组(融合抗菌肽重组酵母菌、IL-2和融合抗菌肽重组酵母菌)小鼠的生长明显优于对照组(空质粒酵母菌)(P 0. 05),且血清Ig G、Ig G1和Ig G2a含量显著升高(P 0. 05); TLR1、TLR4、TLR6、TLR9、IL-7、IL-15、IL-23、CD62L、IL-2、IL-4、IL-6、IL-12、CRP4和CAMP基因的表达水平显著增加(P 0. 05)。同时,处理组小鼠血液白细胞Th和Tc细胞明显增多(P 0. 05),免疫力和存活率均明显高于对照组(P 0. 05)。重组酵母菌能有效增强小鼠的先天和获得性免疫力,促进生长,可进一步开发成安全有效的免疫调节生物制剂,改善动物的生长和免疫力。     

蛋氨酸脑啡肽联合白细胞介素-2抗肿瘤作用研究

观察蛋氨酸脑啡肽(MEK)和注射用白细胞介素-2(IL-2)单独和联合应用的抗肿瘤效应。应用动物移植性肿瘤的体内试验法,分别观察MEK、IL-2和(MEK+IL-2)对肿瘤的抑瘤作用及小鼠生命延长率情况。MEK组、IL-2组和(MEK+IL-2)组的抑瘤作用分别为131.38%(P0.01)、69.63%(P0.01)、229.170%(P0.01),都有显著差异;生命延长率为:MEK组18.27%(P0.01),有显著差异;IL-2组9.31%(P0.01),无显著差异;(MEK+IL-2)组32.07%(P0.01),有显著差异。结果表明:MEK、IL-2和(MEK+IL-2)都对小鼠移植性瘤有一定的抑制作用,MEK和(MEK+IL-2)能够延长小鼠生命,而IL-2单独应用不能延长小鼠生命;MEK和IL-2联合应用时作用相加,而不良反应未相加。     

白细胞介素22的研究进展

白细胞介素-22（IL-22）起初系在鼠T淋巴细胞中经IL-9诱生而获得的,并因此被命名为IL-TIF（IL-10-related -derived inducible factor);鉴于其与IL-10的结构相似性,其受体是一个巳建立的细胞因子受体家族的新成员,以及其在白细胞内的产物和作用的确认,2000年由Xie等提出将其命名为一个新的人类细胞因子白细胞介素-22（IL-22）。实验证明IL-22上调肝细胞急性期产物,参与炎症反应。借助IL-9或CD3抗体和刀豆蛋白A的激活,T细胞、肥大细胞、胸腺和脑均可表达IL-22,表明这个因子在免疫系统内外可能显示多效的活性,在抗体免疫应答中,其对来自TH2T细胞的IL-4产物有适当的抑制作用,对于哮喘有潜在的治疗作用。在信号转导途径中,IL-22能介导STAT1、STAT3和STAT5的激活。     

白细胞介素-6在急性胰腺炎中的作用及其机制研究

目的:明确白细胞介素-6(IL-6)在小鼠急性胰腺炎中的作用及其机制研究。方法:通过胰胆管结扎的方法诱导小鼠急性胰腺炎;分离小鼠胰腺腺泡细胞。采用ELISA方法检测胰腺组织或腺泡细胞裂解物中的细胞因子;通过western blot分析检测组织或细胞中IL-6或ERK表达。结果:IL-6浓度在胰腺组织和腺泡细胞中显著增加(P0.05)。在离体原代小鼠腺泡细胞,TNF-α刺激增加IL-6释放(P0.05);与此同时,IL-6刺激可增加其它促炎性细胞因子的释放,两者都涉及ERK MAP激酶通路。黄酮类化合物木犀草素抑制IL-6刺激引起白细胞介素-6(IL-6)和人巨嗜细胞激活蛋白-1(CCL2/MCP-1)释放。最后进一步证实,IL-6激活人胰腺组织中的ERK。结论:IL-6在急性胰腺炎中增加,激活炎症通路并加重急性胰腺炎。     

地塞米松对哮喘豚鼠血清白细胞介素-4 变化及肺组织形态的影响

目的:观察地塞米松对哮喘豚鼠血清白细胞介素-4(IL-4)及肺组织形态的影响,探讨糖皮质激素治疗哮喘的机制。方法:30只健康雄性Hartley系豚鼠随机分为空白对照组,病理模型组,地塞米松组。用卵白蛋白(OVA)复制哮喘豚鼠模型。采用流式细胞术分析CD4+interleukin-4(IL-4)细胞占CD4+T细胞的比例,光镜检查肺组织形态变化。结果:病理模型组外周血中IL-4明显高于空白对照组(P<0.05),地塞米松组外周血中IL-4较病理模型组明显降低(P<0.05),且地塞米松组支气管上皮损伤,粘液腺增生等病理改变较病理模型组明显改善。结论:地塞米松治疗哮喘的作用与抑制Th2的活化,改善支气管上皮损伤,粘液腺增生等病理改变有关。     

Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model

We introduced the interleukin-12 (IL-12) gene into the mouse bladder cancer cell line (MBT2) to establish sublines that secrete bioactive IL-12. IL-12-secreting MBT2 (MBT2/IL-12) sublines were completely rejected when subcutaneously implanted into immunocompetent syngeneic C3H mice. Although this antitumor effect did not change when IL-12-secreting cells were injected into immunodeficient mice whose CD8⁺ T or CD4⁺ T cells had been depleted by the corresponding antibody, it was abrogated when natural killer cells were depleted by anti-asialoGM1 antibody. In addition, when parental MBT2 cells mixed with MBT2/IL-12 cells were subcutaneously injected into mice, admixed MBT2/IL-12 inhibited the growth of the parental tumor. Furthermore, this antitumor effect was enhanced by systemic IL-18 administration. This synergism was abrogated when the mice were treated with interferon-γ-neutralizing antibody in vivo. In conclusion, local secretion of IL-12 led to effective antitumor activity that was enhanced by systemic administration of IL-18. Interferon-γ plays an important role in the synergism of IL-12 gene transduction and systemic administration of IL-18. Received: 7 May 1998 / Accepted: 27 May 1999     

Thrombopoietic activity of human interleukin-6

Thrombopoietin (TPO), a regulatory factor in platelet production, was purified from the conditioned medium of TNK-01 cells cultured in the presence of human interleukin-1. The N-terminal sequence of purified TPO was determined to be VPPGEDSKDVAAPHRQPLT, identical to that of the N-terminal region of human interleukin-6 (IL-6). Two forms of TPO with molecular masses of 24 and 27 kDa were identified as IL-6 by Western analysis using an anti-IL-6 antibody. Commercial recombinant human IL-6 produced in Escherichia coli, stimulated megakaryocyte colony formation in the presence of mouse interleukin-3 and increased the number of peripheral platelets in mice in a dose-dependent manner. From these results, it is concluded that human IL-6 has thrombopoietic activity.     

Monoclonal antibody selection for interleukin-4 quantification using suspension arrays and forward-phase protein microarrays

A recombinant mouse interleukin-4 (IL-4) and three different purified rat antimouse IL-4 monoclonal antibodies (Mab) with different clonalities were employed as a model system. This system was used to examine monoclonal antibody effectiveness using both conventional and high-throughput measurement techniques to select antibodies for attaining the most sensitive detection of the recombinant IL-4 through the "sandwich-type" immunoassays. Surface plasmon resonance (SPR) measurements and two high-throughput methods, suspension arrays (also called multiplexed bead arrays) and forward-phase protein microarrays, predicted the same capture (BVD4-1D11) and detection (BVD6-24G2) antibody pair for the most sensitive detection of the recombinant cytokine. By using this antibody pair, we were able to detect as low as 2 pg/mL of IL-4 in buffer solution and 13.5 pg/mL of IL-4 spiked in 100% normal mouse serum with the multiplexed bead arrays. Due to the large amount of material required for SPR measurements, the study suggests that the multiplexed bead arrays and protein microarrays are both suited for the selection of numerous antibodies against the same analyte of interest to meet the need in the areas of systems biology and reproducible clinical diagnostics for better patient care.     

Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells

Summary The activity of lymphokine-activated killer (LAK) cells is supported by various cytokines. The objective of this study was to see if recombinant interleukin-6 (IL-6) either alone or in combination with interleukin-2 (IL-2) has any effect on the generation of LAK cells. Peripheral blood mononuclear cells of healthy donors were cultured for 4 or 6 days with both cytokines either alone or in combination. LAK activity against K562 and natural killer-resistant Daudi cells was assessed by a 4-h and an 18-h⁵¹Cr-release assay at various effector to target ratios. IL-6 alone in increasing concentrations did not induce LAK cell activity. Neither additive nor synergistic effects of IL-6 with IL-2 were observed. Immunofluorescence analysis with phycoerythrin-conjugated anti-CD56 antibody demonstrated that IL-6 could not maintain or increase the number of CD56-positive cells over a 6-day culture period. These results suggest that IL-6 does not support LAK cell generation by itself or increase LAK cell activity in combination with IL-2.     

The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon.

The injection of 20 ng of mouse interleukin-12 (IL-12) protects mice from a lethal infection with encephalomyocarditis virus. In vitro, an anti-gamma interferon (anti-IFN-gamma) monoclonal antibody but not an anti-IL-12 monoclonal antibody neutralizes the antiviral activity present in the supernatants of splenocytes stimulated with IL-12. Finally, IL-12 fails to protect 129 Sv/Ev IFN-gamma R0/0 mice against encephalomyocarditis virus infection. These results demonstrate that IL-12 exerts its antiviral activity through the induction of endogenous IFN-gamma.     

Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12

Immunologic effector cells termed cytokine-induced killer (CIK) cells are generated in vitro from peripheral blood lymphocytes by addition of interferon-gamma, interleukin (IL)-2, IL-1 and an antibody against CD3. CIK cells have been shown to eradicate established tumors in a SCID mouse/human lymphoma model. CIK cells are dependent on exogenous cytokines such as IL-2, IL-7, or IL-12. We studied the effect of these cytokines in detail. Cellular proliferation was analyzed using an MTT proliferation assay, surface antigen expression via flow cytometry, cytotoxic activity using an LDH release assay, and apoptosis via flow cytometric analysis. IL-2, IL-7 and IL-12 led to significant growth of lymphocytes. Cells grown in IL-2 and IL-7 showed higher proliferation rates than cells grown in IL-12 according to the MTT assay. Concerning surface antigen expression, exogenous IL-7 led to a decrease in IL-7 receptor expression (4.8% from 60.4%) and exogenous IL-2 to a decrease in IL-2 receptor expression (61.2% from 73.2%). CD28 expression was higher in cells grown in IL-7 (77.3%) than in cells grown in IL-2 (62.5%). IL-12 led to a decrease in ICAM-1 adhesion molecule expression (57.7% from 76.7%) and an increase in CD56 expression compared with exogenous IL-7. IL-7 led to higher number of CD4-positive cells than IL-2 (53.0% vs 49.5%). No significant difference was found between IL-2, IL-7 and IL-12 in cytotoxic activity measured in an LDH release assay. Small amounts of apoptotic cells were found with all cytokines. However, the percentage of necrotic cells was higher with exogenous IL-12 than with IL-2 or IL-7. In summary, CIK cells can be generated using exogenous IL-2, IL-7 or IL-12. No difference in cytotoxic activity was found. However, significant differences were found in cell proliferation rates, antigen expression and percentage of necrotic cells. Received: 26 February 1998 / Accepted: 4 August 1998     

Effects of interleukin-12 on in vitro culture with interleukin-2 of regional lymph node lymphocytes from lung cancer patients

 In the present study, we carried out a functional analysis of regional lymph node lymphocytes (RLNL) from patients with lung cancer after in vitro activation by interleukin-2 (IL-2) and interleukin-12 (IL-12). IL-12 (100 U/ml) enhanced both the proliferation and cytotoxic activity of RLNL in a culture with low doses of IL-2 (5 – 10 JRU/ml). After comparing an RLNL culture with a low dose of IL-2 alone, a higher proportion of CD8⁺ cells and CD56⁺ cells and a lower proportion of CD4⁺ cells were found in the culture with both IL-12 and a low dose of IL-2. Such a combination of the cytokines effectively activated RLNL in terms of the expression of IL-2 receptors. In the culture condition of IL-12 and a low dose of IL-2, a synergistic effect was observed in the production of such cytokines as interferon γ, tumor necrosis factor α (TNFα), and TNFβ, as well as in tumor cytotoxicity. However, the addition of IL-12 inhibited the cytotoxicity of RLNL in the culture with a high dose of IL-2 (100 JRU/ml). This inhibition is considered to be partially due to the endogenous production of TNFα by lymphocytes, because the neutralization of TNFα bioactivity partially restored the cytotoxic activities of RLNL. Furthermore, in the presence of hydrocortisone, IL-12 synergistically enhanced the cytotoxic activity of RLNL cultured with a high dose of IL-2. These results provide useful information about the improvement of adoptive immunotherapy against cancer using RLNL. Received: 2 February 1996 / Accepted: 30 July 1996     

Respiratory tract gene transfer. Transplantation of genetically modified T-lymphocytes directly to the respiratory epithelial surface.

To evaluate the strategy for potentially treating respiratory disorders with genetically modified T-lymphocytes, the interleukin-2 (IL-2)-dependent murine T-cell line, CTLL2, was genetically altered with the Escherichia coli beta-galactosidase (beta-gal) gene (lacZ) in vitro with a retroviral vector and the modified T-cells were transplanted directly to the respiratory epithelial surface of syngeneic C57Bl/6 mice. Southern and Northern analyses confirmed that the neomycin-selected modified T-cells contained and expressed the lacZ gene. The fate of the modified T-cells (CTLL2/lacZ) was followed by flow cytometry with T-cell surface marker Thy1.2 and fluorescent beta-gal analysis. One day after transplantation (7.5 x 10(5) CTLL2/lacZ T-cells/g of body weight), 95 +/- 3% of the Thy1.2+ T-cells recovered from respiratory epithelial lining fluid (ELF) were beta-gal+. Importantly, the modified T-cells remained in the lung for some time; at 3 days, Thy1.2+ beta-gal+ T-cells represented 63 +/- 12% of ELF Thy1.2+ T-cells and 59 +/- 6% of Thy1.2+ T-cells recovered from the whole lung. At 7 days, 33 +/- 8% of the Thy 1.2+ cells in ELF and 75 +/- 6% of the Thy1.2+ cells in whole lung were Thy1.2+ beta-gal+. In contrast, the proportion of the Thy1.2+ beta-gal+ T-cells in the spleen, the major extrapulmonary lymphatic organ, never rose above 3 +/- 1% of the total Thy1.2+ cells. The number of Thy1.2+ beta-gal+ T-cells in the lung could be modified by the systemic administration of IL-2, with whole lung Thy1.2+ beta-gal+ T-cells increasing 4.6-fold 3 days after transplantation, compared with non-IL-2-treated animals. These studies suggest that direct transplantation of genetically modified T-cells into the lung is feasible and represents a viable strategy for lung-specific gene transfer.     

Expression of Thy 1 thymocyte differentiation antigen in mouse mammary cancer cells in vitro

Allogeneic AKR-anti C3H Thy 1.2 antigen serum and monoclonal anti-Thy 1.2 and anti-Thy 1.1 antigen antibodies were used to study the expression of lymphocyte differentiation antigen in a clonal mammary carcinoma cell line originated from a GR/mt stable cell line. Both allogeneic antiserum and monoclonal anti-Thy 1.2 (but not Thy 1.1) antibody were active with the hormone-treated fixed cells in an indirect immunofluorescence test. However, antigen on the cellular membranes could be detected only with the use of allogeneic (but not with monoclonal antibody) anti-Thy 1.2 serum.     

Toxoplasma gondii triggers secretion of interleukin-12 but low level of interleukin-10 from the THP-1 human monocytic cell line

Previous studies using both in vitro and in vivo mouse models have demonstrated that a subtle balance between pro- and anti-inflammatory cytokines, among which interleukin-12 (IL-12) and interleukin-10 (IL-10), respectively is crucial to control Toxoplasma infection. However, the few studies performed with human cell lines highlighted important host-related differences in the immune response to Toxoplasma gondii. The goal of our work was thus to study the production of both IL-12 and IL-10 by the THP-1 human monocytic cell line in response to Toxoplasma. We demonstrated that infection by live parasites (RH strain) triggers secretion of IL-12, but low level of IL-10. IL-12 secretion appeared within 8 h, up to 48 h. We also showed that infection by live parasites is not mandatory since heat-killed parasites, crude tachyzoite lysate as well as excreted/secreted antigens induced significant, yet reduced production of IL-12.